Q-omics provides the consensus-scored TMPRSS12 profile across patient tissues and cancer cell-line models. TMPRSS12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMPRSS12 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TMPRSS12 RNA expression shows 11,981 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where TMPRSS12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPRSS12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPRSS12 survival associations across molecular data types. TMPRSS12 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPRSS12 RNA expression–survival associations across cancer types. High TMPRSS12 expression shows unfavorable associations in LIHC, KIRC, BRCA, LGG and LUAD, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for TMPRSS12 RNA expression.
This table summarizes TMPRSS12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMPRSS12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPRSS12 shows lower tumor expression in KIRC, KIRP, HNSC, BRCA and KICH and higher tumor expression in BLCA. The KIRC box plot shows higher TMPRSS12 RNA expression in normal versus tumor tissue (log2 FC = −0.195, t-test p < 0.001).
This table shows molecular features associated with TMPRSS12 in patient tissues and cancer cell lines. In patient samples, TMPRSS12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMPRSS12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_NSCLC_LUSC.
